Johnson & Johnson’s expanded policy to include India for improved access to pediatric HIV drugs - Prometheus IP

May 27, 2015by Usharani0

Janssen Pharmaceuticals, a pharmaceutical company of Johnson & Johnson, has announced an expanded policy on improved accessibility of medicines in which the geographic scope of its earlier 2012 policy of waiving enforcement of patent rights for pediatric formulations of Darunavir, is expanded. This expansion includes many low and middle income countries including India, Pakistan and Sri Lanka. The company has further committed itself to providing technical expertise to Pediatric HIV Treatment Initiative (PHTI) on developing a fixed-dose combination of Darunavir boosted with ritonavir (DRV/r).

Usharani

Dr. Usharani is a registered Patent agent. She holds a M.Sc., M.Phil. degree in Biochemistry and a Doctoral degree in Biosciences. She also holds a Postdoctoral diploma in Intellectual Property Rights and is trained by the World Intellectual Property Organisation (WIPO) in drafting patent applications

Hyderabad
Prometheus Patent Services Pvt Ltd.
Plot No:438, SPR Arcade,
1st Floor, TNGO’s Colony Phase 2
Gachibowli, Hyderabad-500032
Telangana, India.
Our locationsWhere to find us?
https://www.prometheusip.com/wp-content/uploads/2020/01/footer-map.png
Get in touchPrometheus IP Social
Prometheus IPHeadquarters
Prometheus Patent Services Pvt Ltd.
Plot No:438, SPR Arcade,
1st Floor, TNGO’s Colony Phase 2
Gachibowli, Hyderabad-500032
Telangana, India.
Our locationsWhere to find us?
https://www.prometheusip.com/wp-content/uploads/2020/01/footer-map.png
Get in touchPrometheus IP Social

Copyright Prometheus IP. All rights reserved.

Copyright Prometheus IP. All rights reserved.